AKRO250516P60000
- 18.30
- 0.000.00%
Akero Therapeutics Newsroom
Clear Street Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $49
Express News | Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the Easl Congress 2025
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Akero Therapeutics Initiated With a Buy at Clear Street
$AKRO Stock Is up 2% Today. Here's What We See in Our Data.
Insiders At Akero Therapeutics Sold US$1.6m In Stock, Alluding To Potential Weakness
Major Investment Alert: Akero Therapeutics Stock Purchase by Director!
Akero Therapeutics(AKRO.US) Director Buys US$8.79 Million in Common Stock
10 Health Care Stocks Whale Activity In Today's Session
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Raises Target Price to $60
Akero Therapeutics Insider Sold Shares Worth $2,243,213, According to a Recent SEC Filing
Insider Sale: Chief Operating Officer of $AKRO Sells 11,447 Shares
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings
Express News | Akero Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $75 From $72
Akero Therapeutics Price Target Lowered to $90 From $96 at Morgan Stanley
Why Akero Therapeutics, Inc. (AKRO) Is Skyrocketing So Far in 2025
Bank of America Securities Remains a Buy on Akero Therapeutics (AKRO)
LifeSci Capital Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $80